Venture capital firms 4BIO Capital and UPMC led a $52m Series A2 round in SparingVision, a genomic medicine company focused on ocular diseases, joined with Jeito Capital, Ysios Capital, Bpifrance and Foundation Fighting Blindness. “We are delighted to have closed this financing round, which demonstrates the excitement around SparingVision’s lead compound, SPVN06. With its singular mutation-agnostic approach, SPVN06 could have a much broader commercial potential than most gene therapy products for RP currently in development and will be used as an anchor to build an economically-viable portfolio of therapies in the field of ophthalmology. Our shareholders, both new and existing, are all long-term, strategic and patient-centric investors that share our vision and we are excited to be working with them to achieve our goals,” Stephane Boissel, SparingVision’s President and CEO.